1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Astrocytoma - Pipeline Review, H2 2013

Astrocytoma - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 61 pages

Astrocytoma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Astrocytoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. Astrocytoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Astrocytoma.
- A review of the Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Astrocytoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Astrocytoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Astrocytoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Astrocytoma - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Astrocytoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Astrocytoma 7
Astrocytoma Therapeutics under Development by Companies 9
Astrocytoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Astrocytoma Therapeutics - Products under Development by Companies 14
Astrocytoma Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Astrocytoma Therapeutics Development 16
Exelixis, Inc. 16
Threshold Pharmaceuticals, Inc. 17
Axelar AB 18
Astrocytoma - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
cabozantinib (S)-malate - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
TH-302 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
carmustine SR - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
pritumumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
P-798 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Mer Receptor Tyrosine Kinase Inhibitors - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Mer Antibody - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Astrocytoma Therapeutics - Drug Profile Updates 40
Astrocytoma Therapeutics - Dormant Products 55
Astrocytoma - Product Development Milestones 56
Featured News and Press Releases 56
Jan 21, 2013: Axelar Initiates Phase I/II Study Of AXL1717 In Patients With Malignant Astrocytomas In US 56
Jul 25, 2011: Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab 56
Nov 03, 2010: Novartis Reports Study In NEJM Shows Afinitor Reduces Size Of SEGAs, Benign Brain Tumors Associated With Tuberous Sclerosis 57
Jun 08, 2010: Graham's Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs 58
Jun 08, 2010: Graham's Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables

Number of Products Under Development for Astrocytoma, H2 2013 7
Products under Development for Astrocytoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Exelixis, Inc., H2 2013 16
Threshold Pharmaceuticals, Inc., H2 2013 17
Axelar AB, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 23
Astrocytoma Therapeutics - Drug Profile Updates 40
Astrocytoma Therapeutics - Dormant Products 55

List of Figures

Number of Products under Development for Astrocytoma, H2 2013 7
Products under Development for Astrocytoma - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Discovery and Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 19
Assessment by Route of Administration, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Molecule Type, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.